{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-110066","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.475005+00:00","generated_at":"2026-05-31T01:23:16.502266+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Achieve Life Sciences enters $50M ATM equity offering with Jefferies for cytisinicline","bullets":["Entered Open Market Sale Agreement with Jefferies for at-the-market offering of up to $50M of common stock.","Jefferies receives up to 3% commission; company has no obligation to sell and may suspend at any time.","Proceeds to fund clinical development of cytisinicline for smoking cessation and general corporate purposes.","Offering made under existing S-3 registration statement filed June 28, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-110066","json":"https://secwatch.observer/filing/0000950170-24-110066.json","markdown":"https://secwatch.observer/filing/0000950170-24-110066.md","text":"https://secwatch.observer/filing/0000950170-24-110066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017024110066/0000950170-24-110066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017024110066/achv-20240927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:23:16.502266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}